CytoSorbents Corporation (CTSO)

[techxen]

Pediatric septic shock

I could not find this as one of the weekly case studies that have been published this year. Since January, the company has published 46 case studies. The last pediatric case that the company formally presented was back in November of 2015 during the Q3 earnings call. It was a 4 year old girl who had developed toxic shock syndrome after an insect bite. She had extensive capillary leak syndrome, was progressing towards scalded skin syndrome, which is akin to having a massive burn injury all over the body. She made a complete recovery after three weeks and CytoSorb was credited with helping to save for the life and helping to prevent an amputation for leg. The case was later presented at the Hungarian Pediatric Congress.

The use of Cytosorb in treating pediatric patients is an area I would think the company definitely has an interest in and is studying as some of the board members and officers have a background in this area. Dr. Paul Checchia, who is on the company's Cardiac Surgery Board, is the Medical Director of the Pediatric Cardiovascular ICU at Texas Children's Hospital in Houston.  He is also Professor of Pediatric Critical Care Medicine and Pediatric Cardiology at Baylor College of Medicine.  Also Gregory Di Russo whom the company hired as Senior VP of Clinical Development, is an accomplished pediatric cardiothoracic surgeon specializing in congenital cardiac surgery, and was Vice Chairman of Cardiothoracic Surgery at the Children's National Medical Center in Washington, D.C.